Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

Panelists discuss how the phase 3 FURTHER trial evaluated firmonertinib in EGFR PACC-mutated non–small cell lung cancer (NSCLC), showing encouraging efficacy across subgroups and manageable safety.

Panelists discuss how response rates were particularly strong in more frequent variants like G719X and S768I, as well as in compound mutations and patients with central nervous system involvement.

Panelists discuss how these findings suggest a meaningful improvement over existing standards of care, highlighting firmonertinib’s potential as a preferred option pending broader regulatory approval.